Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Hypometilating Agents (HMA) As Salvage Therapy in Relapsed or Refractory AML: A 5-Center Retrospective Study

Marica Laurino, MD, Federica Lessi, MD, Antonio Branca, MD, Silvia Imbergamo, MD, Elena Crisà, Anna Candoni, MD, Davide Lazzarotto, MD, Michele Gottardi, MD, Cristina Papayannidis, MD PhD, Gianpietro Semenzato, MD

Blood (2017) 130 (Supplement 1): 5051.

https://doi.org/10.1182/blood.V130.Suppl_1.5051.5051

Published: 2017

Journal Articles

Myeloma Lytic Bone Lesions Characterization with WB-LDCT and 18 f-FDG PET/MRI

Albana Lico, MD, Gregorio Barilà, MD, Filippo Crimì, MD, Lucia Checuz, MD, Tamara Berno, MD, Stefania Vio, MD, Antonio Branca, MD, Lucia Ammirati, MD, Matteo Leoncin, MD, Pietro Zucchetta, MD, Carmelo Lacognata, MD, Francesco Piazza, MD, Gianpietro Semenzato, MD, Renato Zambello, MD

Blood (2017) 130 (Supplement 1): 1788.

https://doi.org/10.1182/blood.V130.Suppl_1.1788.1788

Published: 2017

Journal Articles

Autologous Stem Cell Transplantation in Newly Diagnosed Elderly Multiple Myeloma Patients: A Single Centre Experience

Tamara Berno, MD, Marcello Riva, MD, Lucia Ammirati, MD, Luca Brugnaro, Dr, Carmela Gurrieri, MD, Antonio Branca, MD, Nabergoj Mitja, MD, Andrea Visentin, MD, Silvia Imbergamo, MD, Francesco Piazza, MD, Livio Trentin, MD, Renato Zambello, MD, Gianpietro Semenzato, MD

Blood (2017) 130 (Supplement 1): 5532.

https://doi.org/10.1182/blood.V130.Suppl_1.5532.5532

Published: 2017

Journal Articles

Rigosertib, a Pan RAS Inhibitor, Decreases Mouse and Human Myeloma Cell Growth in Preclinical Models

Maurizio Zangari, MD, Ikjae Shin, PhD, Antonio Branca, MD, Hanna Yoo, MS, Sophia Fallo, Faith E Davies, MD, Benjamin Hoffman, PhD, Steven M. Fruchtman, MD, Donghoon Yoon, PhD

Blood (2016) 128 (22): 5664.

https://doi.org/10.1182/blood.V128.22.5664.5664

Published: 2016

Journal Articles

Daratumumab Single Agent and Daratumumab Plus Pomalidomide and Dexametasone in Relapsed/Refractory Multiple Myeloma: A Real Life Retrospective Evaluation

Antonio Branca, MD, Amy Buros, PhD, Donghoon Yoon, PhD, Larry J Suva, PhD, Niels Weinhold, PhD, Leo Rasche, MD, Carolina Schinke, MD, Sharmilan Thanendrarajan, MD, Meera Mohan, MD, Cerisse Harcourt, APRN, OCN, Faith E Davies, MD, Frits van Rhee, MD PhD, Gareth J Morgan, MD PhD, Maurizio Zangari, MD

Blood (2016) 128 (22): 4516.

https://doi.org/10.1182/blood.V128.22.4516.4516

Published: 2016

Journal Articles

Phenotypic Heterogeneity of Chronic Lymphoproliferative Disorder of NK Cells

Barila' Gregorio, MD, Antonella Teramo, PhD, Giulia Calabretto, BS, Chiara Ercolin, BS, Albana Lico, MD, Antonio Branca, MD, Tamara Berno, MD, Anna Cabrelle, BS, Elisa Boscaro, BS, Monica Facco, MS, Livio Trentin, MD, Francesco Piazza, MD, Gianpietro Semenzato, Renato Zambello

Blood (2015) 126 (23): 3876.

https://doi.org/10.1182/blood.V126.23.3876.3876

Published: 2015

Journal Articles

Rituximab-Bendamustine Cytarabine (R-BAC) As Frontline Therapy in Mantle Cell Lymphoma: A Single-Center Experience

Antonio Branca, MD, Ilaria Gianesello, MD, Luca Brugnaro, RN, Tamara Berno, MD, Silvia Imbergamo, MD, Federica Lessi, MD, Kety Sammartin, MD, Fabrizio Vianello, MD, Fausto Adami, MD, Gianni Binotto, Carmela Gurrieri, MD, Livio Trentin, MD, Carlo Visco, MD, Renato Zambello, Francesco Piazza, MD, Gianpietro Semenzato

Blood (2015) 126 (23): 2710.

https://doi.org/10.1182/blood.V126.23.2710.2710

Published: 2015

Journal Articles

R-Vemp Is a Safe and Effective Chemo-Immunotherapeutic Regimen In Elderly Unfit DLBCL Patients: Report From a Single Center-Experience

Francesca Pavanello, MD, Antonio Branca, MD, Anna Colpo, MD, Marco Pizzi, MD, Rocco Cappellesso, MD, Ilaria Gianesello, MD, Elena De March, MD, Livio Trentin, MD, Gianpietro Semenzato, MD, Francesco Piazza, MD

Blood (2013) 122 (21): 3042.

https://doi.org/10.1182/blood.V122.21.3042.3042

Published: 2013

Journal Articles

EUTOS Score Predicts Optimal Response To Imatinib According To The Revised ELN Recommendations Better Than Sokal Score: A Study From The “Gruppo Triveneto LMC”

Mario Tiribelli, MD, Massimiliano Bonifacio, MD, Gianni Binotto, MD, Elisabetta Calistri, MD, Elena Maino, MD, Roberta Zanotti, MD, Antonio Branca, MD, Marta Medeot, MD, Gianpietro Semenzato, MD, Giovanni Pizzolo, MD, Renato Fanin, MD

Blood (2013) 122 (21): 4024.

https://doi.org/10.1182/blood.V122.21.4024.4024

Published: 2013

Journal Articles

LGL Disorders: From An Inflammatory-Mediated To a Self-Maintaining Proliferation

Antonella Teramo, PhD, Cristina Gattazzo, PhD, Francesca Passeri, BS, Gregorio Barilà, MD, Enrica Bovo, MD, Chiara Nardin, Alberto Campagnaro, Anna Cabrelle, PhD, Veronica Martini, PhD, Elisa Boscaro, PhD, Antonio Branca, MD, Monica Facco, PhD, Livio Trentin, MD, Gianpietro Semenzato, MD, Renato Zambello, MD

Blood (2013) 122 (21): 4889.

https://doi.org/10.1182/blood.V122.21.4889.4889

Published: 2013

Journal Articles

EUTOS Score Identifies Cases with Poor Outcome in Patients with Early Chronic Phase Chronic Myeloid Leukemia, Though Not Predictive for Optimal Response to Imatinib

Mario Tiribelli, Massimiliano Bonifacio, Elisabetta Calistri, Gianni Binotto, Elena Maino, Luciana Marin, Emanuele Guardalben, Antonio Branca, Filippo Gherlinzoni, MD, Gianpietro Semenzato, Renato Bassan, MD, Giovanni Pizzolo, MD, Renato Fanin

Blood (2012) 120 (21): 3778.

https://doi.org/10.1182/blood.V120.21.3778.3778

Published: 2012

Journal Articles

Heme Oxygenase 1-Induced Resistance to Imatinib In Chronic Myelogenous Leukemia Cells

Daniele Tibullo, Ignazio Barbagallo, Antonio Branca, Cesarina Giallongo, Piera La Cava, Giovanni Li Volti, Giuseppe A Palumbo, MD, Roberto Motterlini, Sr., Angelo Vanella, Sr., Francesco Di Raimondo, MD

Blood (2011) 118 (21): 4410.

https://doi.org/10.1182/blood.V118.21.4410.4410

Published: 2011

Journal Articles

Mechanisms of Heme Oxygenase 1-Induced Resistance to Imatinib In CML Cells.

Daniele Tibullo, Ignazio Barbagallo, Antonio Branca, Cesarina Giallongo, Piera La Cava, PhD, Nunziatina Parrinello, Giovanni Li Volti, Angelo Vanella, Fabio Stagno, MD, Giuseppe A Palumbo, MD, Francesco Di Raimondo

Blood (2010) 116 (21): 3385.

https://doi.org/10.1182/blood.V116.21.3385.3385

Published: 2010

Journal Articles

Effects of the Second Generation Tyrosin Kinase Inhibitors on Osteogenic Differentiation.

Daniele Tibullo, Ignazio Barbagallo, Cesarina Giallongo, Piera La Cava, PhD, Antonio Branca, Concetta Conticello, MD, Fabio Stagno, MD, Annalisa Chiarenza, MD, Giuseppe A Palumbo, MD, Francesco Di Raimondo

Blood (2010) 116 (21): 3386.

https://doi.org/10.1182/blood.V116.21.3386.3386

Published: 2010

NARROW

Hypometilating Agents (HMA) As Salvage Therapy in Relapsed or Refractory AML: A 5-Center Retrospective Study

Myeloma Lytic Bone Lesions Characterization with WB-LDCT and 18 f-FDG PET/MRI

Autologous Stem Cell Transplantation in Newly Diagnosed Elderly Multiple Myeloma Patients: A Single Centre Experience

Rigosertib, a Pan RAS Inhibitor, Decreases Mouse and Human Myeloma Cell Growth in Preclinical Models

Daratumumab Single Agent and Daratumumab Plus Pomalidomide and Dexametasone in Relapsed/Refractory Multiple Myeloma: A Real Life Retrospective Evaluation

Phenotypic Heterogeneity of Chronic Lymphoproliferative Disorder of NK Cells

Rituximab-Bendamustine Cytarabine (R-BAC) As Frontline Therapy in Mantle Cell Lymphoma: A Single-Center Experience

R-Vemp Is a Safe and Effective Chemo-Immunotherapeutic Regimen In Elderly Unfit DLBCL Patients: Report From a Single Center-Experience

EUTOS Score Predicts Optimal Response To Imatinib According To The Revised ELN Recommendations Better Than Sokal Score: A Study From The “Gruppo Triveneto LMC”

LGL Disorders: From An Inflammatory-Mediated To a Self-Maintaining Proliferation

EUTOS Score Identifies Cases with Poor Outcome in Patients with Early Chronic Phase Chronic Myeloid Leukemia, Though Not Predictive for Optimal Response to Imatinib

Heme Oxygenase 1-Induced Resistance to Imatinib In Chronic Myelogenous Leukemia Cells

Mechanisms of Heme Oxygenase 1-Induced Resistance to Imatinib In CML Cells.

Effects of the Second Generation Tyrosin Kinase Inhibitors on Osteogenic Differentiation.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only